Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM1002 in T2DM inadequately controlled with diet and exercise
NCT07193459Phase 3Recruiting
- Sponsor
- Huadong Medicine
- Start
- Aug 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of conveglipron in type 2 diabetes mellitus (T2DM), sponsored by Huadong Medicine. Started Aug 2025; status: recruiting.
02
Drugs
conveglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07193459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07193459.